Rachel, John, etc. re: CCM - I read of Araim Pharma completing phase II of their clinical trials for their drug cibinetide which looks very promising for actually reversing neuropathy and regenerating nerves in conjunction with selective stem dell therapy. If you google cibinetide you will find lots of info. The use of CCM as a non-invasive form of SFN diagnosis is a welcome tool. My neurologist is affiliated with a large university hospital, I just wonder how selective the screening is. It would be good to know if my SFN has improved, worsened or if it remains the same. Rachel, I wonder if you would be a candidate for a clinical trial with this drug? Helen